Mizuho analyst Ann Hynes raised the firm’s price target on Encompass Health to $69 from $65 and keeps a Buy rating on the shares. The analyst views the company’s guidance for labor pressures as conservative and believes it increases earnings visibility going forward. The firm cites strong revenue growth coupled with the continued improvement in labor trends for the target raise.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on EHC:
- Encompass Health price target raised to $73 from $68 at UBS
- Encompass Health sees FY23 adjusted EPS $2.87-$3.16, consensus $3.25
- Encompass Health reports results for fourth quarter 2022 and issues full-year 2023 guidance
- Encompass Health reports Q4 adjusted EPS 88c, consensus 83c
- Encompass Health added to Analyst Current Favorites list at Raymond James
